2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Body Weight D001835 333 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Tibial Fractures D013978 4 associated lipids
Thrombosis D013927 49 associated lipids
Endometriosis D004715 29 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Hypertension D006973 115 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Carotid Artery Thrombosis D002341 7 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Angina, Unstable D000789 14 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Ascites D001201 25 associated lipids
Down Syndrome D004314 18 associated lipids
Bartter Syndrome D001477 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Pregnancy Complications D011248 19 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Diseases in Twins D004200 4 associated lipids
Pulmonary Heart Disease D011660 2 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Ritter JM et al. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. 1989 Br J Clin Pharmacol pmid:2590611
Regan CL et al. Reduced fetal exposure to aspirin using a novel controlled-release preparation in normotensive and hypertensive pregnancies. 1998 Br J Obstet Gynaecol pmid:9692413
Reilly IA et al. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. 1986 Br Med J (Clin Res Ed) pmid:3083991
Aitokallio-Tallberg A et al. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. 1989 Br. J. Cancer pmid:2803956
Kaaja R et al. Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins. 2001 Br. J. Haematol. pmid:11552994
Rousson D et al. Increased in vivo biosynthesis of prostacyclin and thromboxane A2 in chronic idiopathic thrombocytopenic purpura. 1989 Br. J. Haematol. pmid:2669929
Ward PS et al. Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1. 1991 Br. J. Pharmacol. pmid:1933130
Henrion D et al. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. 1997 Br. J. Pharmacol. pmid:9146891
Zhao L et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. 2009 Br. J. Pharmacol. pmid:19220291
Aitokallio-Tallberg AM et al. Urinary excretion of degradation products of prostacyclin and thromboxane is increased in patients with gestational choriocarcinoma. 1991 Cancer Res. pmid:1868436
Arvola P et al. Exercise enhances vasorelaxation in experimental obesity associated hypertension. 1999 Cardiovasc. Res. pmid:10615427
Foudi N et al. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. 2009 Cardiovasc. Res. pmid:18952694
Wennmalm A et al. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. 1991 Circulation pmid:2022025
Fitzgerald DJ et al. Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. 1987 Circulation pmid:3552297
RÃ¥ngemark C et al. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. 1992 Circulation pmid:1423963
Fitzgerald DJ et al. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. 1984 Circulation pmid:6428771
Adatia I et al. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. 1993 Circulation pmid:8222105
Belton O et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. 2000 Circulation pmid:10952950
Brown NJ et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. 2000 Circulation pmid:11056091
Capone ML et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 2004 Circulation pmid:15037526